The global antiviral drugs market was valued at US$ 63.8 billion in 2020 and it is expected to be worth around US$ 60.0 billion by 2030.
The global antiviral drugs market was valued at US$ 63.8 billion in 2020 and it is expected to be worth around US$ 60.0 billion by 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38600
Growth Factors
This is owing to the loss of patent protection of drugs and the high R&D investment required for developing antiviral drugs. However, the rising prevalence of viral infections and the presence of a potential pipeline for the treatment of HIV infection are expected to fuel the growth over the forecast period.
The increasing prevalence of influenza with other complications such as viral pneumonia, obesity, and the rising geriatric population drives the market growth. Moreover, pneumonia is one of the major causes of death in children worldwide. According to the WHO, Pneumonia causes 808,694 children’s deaths in 2017, accounting for 15.0% of all deaths of children under 5 years old. It is most prevalent in South Asia and the sub-Saharan African region.
Report Coverage
| Report Scope | Details |
| Market Size | USD 60.0 billion by 2030 |
| Growth Rate | CAGR of -0.5% From 2021 to 2030 |
| Base Year | 2021 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Drug class, Type, Application |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Gilead Sciences, Inc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Cipla Inc.; Aurobindo Pharma; Dr. Reddy’s Laboratories Ltd. |
Antiviral Drugs Market Trends
The COVID-19 pandemic has boosted antiviral medicine sales. The market is growing due to a sudden rise in the number of COVID-19 cases and the primary focus of medical facilities on the treatment of COVID-19 patients. Furthermore, several pharmaceutical companies are focusing on new drug development in order to provide more effective treatment and better patient results. For instance, Cipla Inc. teamed with Gilead Sciences in May 2020 to manufacture and distribute remdesivir to treat COVID-19 patients in over 127 countries. As a result, aggressive collaborations and strategic efforts by market competitors to widen their antiviral medication manufacturing capacities in order to serve a large patient base have fueled the global market share.
The global anti-viral medications market share is being pushed by an increase in the reported rate of viral disorders. Furthermore, an increase in R&D activities and the expansion of more recent and updated details, like vaccinations and combined therapy, are expected to drive the antiviral drug market.
The production of a safe, efficient, and targeted antiviral from the structure to the ground requires time and limits the market revenue and profit. Potential viral pandemics emphasize the need for broad-spectrum antiviral medications, such as direct-acting antivirals, that can be rapidly deployed on a large scale to prevent viral spread until adequate vaccines are developed. Increasing infection prevention methods and vaccination accessibility knowledge is also expected to restrict the market of antiviral drugs.
Increased partnerships for antiviral drug development and manufacturing are expected to result in the development of several innovative drugs in the forecast period. The leading competitors in the market are collaborating on the research and development of innovative treatments to reduce the strain of virus antiviral drugs. For instance, In December 2021, Cipla Limited announced the acquisition of approximately 33% of an equity stake in Clean Max Auriga Power Limited Liability Partnership. The agreement is aligned with the business’ goal to grow the use of renewable resources in its activities and to achieve the legal standards for just being a captive user under power generation regulations.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/38600
Drug Class Insights
The reverse transcriptase inhibitors segment dominated the market for antiviral drugs and accounted for the largest revenue share of 50% in 2021. The segment is anticipated to maintain its dominance over the forecast period. The high share of reverse transcriptase inhibitors can be attributed to the increasing diagnosis and treatment rate of HIV, as these medicines are mainly used to treat HIV infection and the high effectiveness of these drugs against viral infections. Moreover, the presence of reverse transcriptase inhibitors in the pipeline will fuel the demand for these drugs in the coming years. The drug class includes Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
The protease inhibitors segment held the second-largest revenue share in 2020 and is anticipated to witness a CAGR of -1.4% over the forecast period. The decline in the segment growth can be attributed to increasing vaccination against viral infections and reduced R&D activities in the development of protease inhibitors.
Type Insights
The branded segment dominated the market and accounted for the largest revenue share of 57.2% in 2020. The segment is expected to maintain its dominance over the forecast period. Branded antiviral medicines such as Biktarvy, Genvoya, Triumeq, Mavyret, and Prezista hold a significant share of the market. The high adoption rate of branded drugs in the North American and European markets and the high cost of drugs are expected to drive the segment.
Increasing demand for the generic version of antiviral drugs in developing countries due to its cost-effectiveness is driving the generics segment. The generic antiviral drugs segment is highly competitive and price-sensitive. The presence of a large number of generic pharmaceutical manufacturers such as Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Mylan, and others make the market highly competitive for generic antiviral drugs.
Application Insights
The HIV segment dominated the market and held the largest revenue share of 45% in 2021. The segment is expected to witness the fastest growth rate over the forecast period. The high prevalence of HIV infection coupled with a high treatment rate, presence of branded drugs, and government initiatives to increase the treatment rate is estimated to drive the market at a higher growth rate. For instance, in 2019, the U.S. government announced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2030. The initiative seeks to reduce HIV infections and improve the diagnosis and treatment rate in the U.S. Moreover, the presence of strong pipeline drugs for HIV infection will also fuel market growth over the forecast period.
The hepatitis segment held the second-largest revenue share in 2021. Increasing vaccination against hepatitis A and B is affecting the growth adversely. Moreover, the outbreak of the COVID-19 pandemic has significantly increased the growth of the others segment in 2020. Due to COVID-19, the others segment share increased from 6.3% to 23.5% from 2019 to 2020.
Regional Insights
North America dominated the market and accounted for the largest revenue share in 2021.The market decline can be attributed to the loss of market exclusivity of branded drugs, increasing vaccination rate against viral infections, and government initiatives to reduce the incidence of viral infections. For instance, the U.S. government is undertaking various measures including investment in infectious diseases programs and promoting the R&D activities of innovative therapies to manage viral infections.
In Asia Pacific, the market for antiviral drugs is anticipated to witness the fastest growth rate during the forecast period. The high growth of the market can be attributed to the increasing prevalence and treatment rate of viral infections, developing healthcare infrastructure in the region, and increasing awareness among people regarding infectious diseases. Moreover, the strong presence of generic pharmaceutical manufacturing companies in India, China, and other South Asian countries and the increasing geriatric population in the region are some of the key factors driving the segment growth.
Related Reports
- Respiratory Antiviral Treatment Market Report 2022-2030 - https://www.visionresearchreports.com/respiratory-antiviral-treatment-market/38192
- Antiviral Combination Therapies Market Report 2022-2030 - https://www.visionresearchreports.com/antiviral-combination-therapies-market/38190
- Congestive Heart Failure Drugs Market Report 2022-2030 - https://www.visionresearchreports.com/congestive-heart-failure-drugs-market/39835
Key Players
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- AbbVie
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Aurobindo Pharma
- Dr. Reddy’s Laboratories Ltd.
Market Segmentation
- Drug Class
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
- Type
- Branded
- Generics
- Application
- HIV
- Hepatitis
- Herpes
- Influenza
- Others
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/38600
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/